RT Journal Article
SR Electronic
T1 Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.09.20054031
DO 10.1101/2020.04.09.20054031
A1 Olga Nigro
A1 Graziella Pinotti
A1 Federica De Galitiis
A1 Francesca Romana Di Pietro
A1 Raffaele Giusti
A1 Marco Filetti
A1 Melissa Bersanelli
A1 Alessandro Lazzarin
A1 Paola Bordi
A1 Annamaria Catino
A1 Pamela Pizzutilo
A1 Domenico Galetta
A1 Paolo Marchetti
A1 Andrea Botticelli
A1 Simone Scagnoli
A1 Marco Russano
A1 Daniele Santini
A1 Mariangela Torniai
A1 Rossana Berardi
A1 Biagio Ricciuti
A1 Andrea De Giglio
A1 Rita Chiari
A1 Alessandro Russo
A1 Vincenzo Adamo
A1 Marianna Tudini
A1 Rosa Rita Silva
A1 Elena Bolzacchini
A1 Monica Giordano
A1 Pietro Di Marino
A1 Michele De Tursi
A1 Erika Rijavec
A1 Michele Ghidini
A1 Ilaria Vallini
A1 Luigia Stefania Stucci
A1 Marco Tucci
A1 Laura Pala
A1 Fabio Conforti
A1 Paola Queirolo
A1 Enrica Tanda
A1 Francesco Spagnolo
A1 Federica Cecchi
A1 Sergio Bracarda
A1 Serena Macrini
A1 Matteo Santoni
A1 Nicola Battelli
A1 Maria Concetta Fargnoli
A1 Giampiero Porzio
A1 Alessandro Tuzi
A1 Matteo Basilio Suter
A1 Corrado Ficorella
A1 Alessio Cortellini
YR 2020
UL http://medrxiv.org/content/early/2020/04/14/2020.04.09.20054031.abstract
AB Data on spectrum and grade of immune-related adverse events (irAEs) in long-term responders to immune checkpoint inhibitors (ICI) are lacking.We performed a retrospective multicenter study to characterized irAEs occurring after a 12-months minimum treatment period with PD-(L)1 ICIs in advanced cancer patients. IrAEs were categorized into “early” (≤12 months) and “late” (>12 months).From September 2013 to October 2019, 436 consecutive patients were evaluated. 223 experienced any grade early-irAEs (51.1%), while 132 experienced any grade late-irAEs (30.3%) (p < 0.0001). Among the latter, 29 (22%) experienced a recurrence of an early-irAEs, while 103 (78%) experienced de novo late-irAEs involving different system/organ. Among patients with late-irAEs, 21 experienced G3/G4 irAEs (4.8%). Median time to onset of early-irAEs was 3.4 months (95%CI: 2.8-4.2), while the median time to onset of late-irAEs was 16.6 months (95%CI: 15.8-17.6). Cumulative time-adjusted risk of disease progression according to both the early-irAEs (HR = 0.63 [95%CI: 0.30-1.29], p = 0.204) and late-irAEs occurrence revealed no statistically significant differences (HR = 0.75 [95%CI: 0.37-1.56], p = 0.452). Also the time-adjusted cumulative risk of death according to both early-irAEs (HR = 0.79 [95%CI: 0.34-1.86], p = 0.598) and late-irAEs (HR = 0.92 [95%CI: 0.49-1.74], p = 0.811) did not show statistically significant differences.Although less frequent than early-irAEs, late-irAEs are quite common in long responders to PD-(L)1 ICIs, and are different in terms of spectrum and grade. Time-adjusted analysis revealed that the cumulative risk of disease progression and death were not significantly reduced in patients who experienced late-irAEs.Competing Interest StatementDr. Alessio Cortellini received grants as speaker by MSD and Astra-Zeneca; grant consultancies by BMS, Roche, Novartis, Istituto Gentili and Ipsen. Dr. Melissa Bersanelli received research funding by Roche, Pfizer, Seqirus, AstraZeneca, Bristol-Myers Squibb, Novartis and Sanofi; she also received honoraria for advisory role and as speaker at scientific events by Bristol-Myers Squibb, Novartis and Pfizer. Dr. Marco Russano received honoraria for scientific events by Roche, Astrazeneca, Bristol-Myers Squibb, Merck Sharp & Dohme and Boehringer Ingelheim. Dr. Raffaele Giusti Advisory Boards/ Honoraria/ Speakers’ fee/ Consultant for: Astra Zeneca, Roche.Funding StatementNo funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesthe datasets used during the present study are available from the corresponding author upon reasonable request